McGreivy, Jesse

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 1,685

BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis

Verstovsek, S., Al-Ali, H. K., Mascarenhas, J., Perkins, A., Vannucchi, A. M., Mohan, S. R., Scott, B. L., Woszczyk, D., Koschmieder, S., García-Delgado, R., et al. (2022) · Future Oncology

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 41

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis

Mascarenhas, J. O., Popov, V. M., Mohan, S., Özkurt, Z. N., Kiladjian, J.-J., Al-Ali, H. K., Perkins, A., Huang, Z., Qamoos, H., McGreivy, J., et al. (2024) · Blood

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 17

Disease-modifying activity of navtemadlin correlates with clinical responses in a randomized, multicenter, global phase 3 study (BOREAS) in JAK-inhibitor relapsed/refractory myelofibrosis

Mascarenhas, J. O., Bose, P., Hou, H.-A., Homenda, W., Ross, D., Mohan, S. R., Kiladjian, J.-J., Al-Ali, H. K., Perkins, A., Khalina, Y., et al. (2024) · Blood

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 8